Literature DB >> 8502342

The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital haemodialysis.

A Davenport1, R F King, J W Ironside, E J Will, A M Davison.   

Abstract

The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of the anterior tibialis muscle was studied in 10 patients with chronic renal failure treated by regular haemodialysis. Repeat muscle biopsies taken when the target haemoglobin concentration of 11 g/dl was achieved showed an increase in median glycogen content from 35 mg/g fat-free dry muscle to 51 mg/g (p < 0.05). The histological appearance showed a marked improvement in muscle fibre diameters, in particular for the type I fibres and a reduction in cytoarchitectural abnormalities. These changes would be expected to produce an increase in both muscle strength and performance and are most probably a consequence of an increase in muscle oxygen delivery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8502342     DOI: 10.1159/000187284

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  Screening for muscle loss in patients established on peritoneal dialysis using bioimpedance.

Authors:  G H B Greenhall; A Davenport
Journal:  Eur J Clin Nutr       Date:  2016-10-26       Impact factor: 4.016

2.  Erythropoietin enhances whole body lipid oxidation during prolonged exercise in humans.

Authors:  Corinne Caillaud; Philippe Connes; Helmi Ben Saad; Jacques Mercier
Journal:  J Physiol Biochem       Date:  2015-01-09       Impact factor: 4.158

3.  Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.

Authors:  Melissa P Wu; Emanuela Gussoni
Journal:  Muscle Nerve       Date:  2011-01       Impact factor: 3.217

Review 4.  Central and peripheral adaptations to physical training in patients with end-stage renal disease.

Authors:  E J Kouidi
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

5.  A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice.

Authors:  M Collino; E Benetti; M Rogazzo; F Chiazza; R Mastrocola; D Nigro; J C Cutrin; M Aragno; R Fantozzi; M A Minetto; C Thiemermann
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

6.  Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles.

Authors:  Pernille Hojman; Camilla Brolin; Hanne Gissel; Claus Brandt; Bo Zerahn; Bente Klarlund Pedersen; Julie Gehl
Journal:  PLoS One       Date:  2009-06-12       Impact factor: 3.240

7.  The role and regulation of erythropoietin (EPO) and its receptor in skeletal muscle: how much do we really know?

Authors:  Séverine Lamon; Aaron P Russell
Journal:  Front Physiol       Date:  2013-07-15       Impact factor: 4.566

8.  Erythropoietin Does Not Enhance Skeletal Muscle Protein Synthesis Following Exercise in Young and Older Adults.

Authors:  Séverine Lamon; Evelyn Zacharewicz; Emily Arentson-Lantz; Paul A Della Gatta; Lobna Ghobrial; Frederico Gerlinger-Romero; Andrew Garnham; Douglas Paddon-Jones; Aaron P Russell
Journal:  Front Physiol       Date:  2016-07-08       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.